查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468402

體內CRO 市場報告按類型（囓齒動物、非囓齒動物）、GLP 類型（非GLP、GLP 毒理學）、適應症（自體免疫/發炎狀況、疼痛管理、腫瘤、中樞神經系統狀況、糖尿病、肥胖等） 、及地區 2024-2032

In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球體內CRO市場規模達到49億美元。

體內合約研究組織（CRO）是在合約基礎上進行廣泛的生物製藥研究的機構。他們透過提供外包服務支援製藥和生物技術公司開發有效的藥物、疫苗和醫療器材。與體外CRO相比，體內CRO涉及在活體生物體中進行的研究，並進行人體臨床試驗以評估藥物的安全性和有效性，而不是對移除的細胞和組織進行檢查。它們有助於研究機構管理複雜的醫學測試，以最低的成本開發有效的藥物，並透過避免招聘、籌款和臨床準備造成的延誤來最佳化工作流程。因此，體內 CRO 在疼痛管理、腫瘤學以及中樞神經系統 (CNS) 損傷和其他疾病的治療中已廣泛應用。目前，它們分為囓齒動物和非囓齒動物類型。

體內 CRO 市場趨勢：

各種心血管疾病的盛行率不斷增加，特別是在老年族群中，以及對有效藥物和基於腫瘤學的新型診斷和治療療法的需求不斷成長，主要推動了市場的成長。此外，合約研究、開發和製造組織 (CRDMO) 對臨床規模生產活性藥物成分 (API) 的需求不斷成長，以及對生物相似藥而非單株抗體的傾向的轉變，也是其他成長誘導因素。此外，日益嚴重的健康問題促使生技公司與 CRO 合作設計有效的新型疫苗，特別是在 COVID-19 大流行期間，這有助於市場成長。此外，在臨床前活動期間廣泛利用體內 CRO 進行毒理學和藥物動力學研究正在推動市場成長。除此之外，生物等效性的出現、學名藥的快速成長、持續的專利到期以及設計個人化藥物的持續研發 (R&D) 活動正在為市場創造積極的前景。

本報告回答的關鍵問題

  • 2023年全球體內CRO市場規模有多大？
  • 2024-2032年全球體內CRO市場的預期成長率是多少？
  • 推動全球體內CRO市場的關鍵因素是什麼？
  • COVID-19 對全球體內 CRO 市場有何影響？
  • 全球體內 CRO 市場按類型分類是怎樣的？
  • 基於GLP類型的全球體內CRO市場的細分如何？
  • 根據適應症，全球體內 CRO 市場的細分如何？
  • 全球體內CRO市場的關鍵區域有哪些？
  • 全球體內 CRO 市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球體內 CRO 市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 囓齒動物
    • 市場走向
    • 關鍵環節
      • 老鼠
      • 老鼠
      • 其他
    • 市場預測
  • 不囓齒動物
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依 GLP 類型

  • 非GLP
    • 市場走向
    • 關鍵環節
      • 內部
      • 外包
    • 市場預測
  • GLP毒理學
    • 市場走向
    • 關鍵環節
      • 內部
      • 外包
    • 市場預測

第 8 章：市場區隔：依跡象

  • 自體免疫/發炎狀況
    • 市場走向
    • 關鍵環節
      • 類風濕關節炎
      • 多發性硬化症
      • 骨關節炎
      • 急躁性腸症候群
      • 其他
    • 市場預測
  • 疼痛管理
    • 市場走向
    • 關鍵環節
      • 慢性疼痛
      • 急性疼痛
    • 市場預測
  • 腫瘤學
    • 市場走向
    • 關鍵環節
      • 血癌
      • 實體腫瘤
      • 其他
    • 市場預測
  • 中樞神經系統疾病
    • 市場走向
    • 關鍵環節
      • 癲癇
      • 帕金森氏症
      • 亨丁頓舞蹈症
      • 中風
      • 創傷性腦損傷
      • 肌萎縮側索硬化症
      • 肌肉再生
      • 其他
    • 市場預測
  • 糖尿病
    • 市場走向
    • 市場預測
  • 肥胖
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Charles River Laboratories International Inc.
    • Evotec SE
    • ICON plc
    • Iris Pharma (ABIONYX Pharma)
    • Labcorp Drug Development (Laboratory Corporation of America Holdings)
    • North American Science Associates LLC
    • Parexel International Corporation
    • Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
    • Pronexus Analytical AB
    • Syneos Health
    • WuXi AppTec
Product Code: SR112024A6267

The global in-vivo CRO market size reached US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024-2032.

In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services. As compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations. As a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.

In-vivo CRO Market Trends:

The increasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth. Additionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors. Furthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth. Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, GLP type and indication.

Breakup by Type:

Rodent

Rats

Mice

Others

Non-Rodent

Breakup by GLP Type:

Non-GLP

In House

Outsourcing

GLP Toxicology

In House

Outsourcing

Breakup by Indication:

Autoimmune/Inflammation Conditions

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome

Others

Pain Management

Chronic Pain

Acute Pain

Oncology

Blood Cancer

Solid Tumor

Others

CNS Conditions

Epilepsy

Parkinson's Disease

Huntington's Disease

Stroke

Traumatic Brain Injury

ALS

Muscle Regeneration

Others

Diabetes

Obesity

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Evotec SE, ICON plc, Iris Pharma (Abionyx Pharma), Labcorp Drug Development (Laboratory Corporation of America Holdings), North American Science Associates LLC, Parexel International Corporation, Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), Pronexus Analytical AB, Syneos Health and WuXi AppTec.

Key Questions Answered in This Report

  • 1. What was the size of the global in-vivo CRO market in 2023?
  • 2. What is the expected growth rate of the global in-vivo CRO market during 2024-2032?
  • 3. What are the key factors driving the global in-vivo CRO market?
  • 4. What has been the impact of COVID-19 on the global in-vivo CRO market?
  • 5. What is the breakup of the global in-vivo CRO market based on the type?
  • 6. What is the breakup of the global in-vivo CRO market based on the GLP type?
  • 7. What is the breakup of the global in-vivo CRO market based on indication?
  • 8. What are the key regions in the global in-vivo CRO market?
  • 9. Who are the key players/companies in the global in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global In-vivo CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Rodent
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Rats
      • 6.1.2.2 Mice
      • 6.1.2.3 Others
    • 6.1.3 Market Forecast
  • 6.2 Non-Rodent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by GLP Type

  • 7.1 Non-GLP
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 In House
      • 7.1.2.2 Outsourcing
    • 7.1.3 Market Forecast
  • 7.2 GLP Toxicology
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 In House
      • 7.2.2.2 Outsourcing
    • 7.2.3 Market Forecast

8 Market Breakup by Indication

  • 8.1 Autoimmune/Inflammation Conditions
    • 8.1.1 Market Trends
    • 8.1.2 Key Segments
      • 8.1.2.1 Rheumatoid Arthritis
      • 8.1.2.2 Multiple Sclerosis
      • 8.1.2.3 Osteoarthritis
      • 8.1.2.4 Irritable Bowel Syndrome
      • 8.1.2.5 Others
    • 8.1.3 Market Forecast
  • 8.2 Pain Management
    • 8.2.1 Market Trends
    • 8.2.2 Key Segments
      • 8.2.2.1 Chronic Pain
      • 8.2.2.2 Acute Pain
    • 8.2.3 Market Forecast
  • 8.3 Oncology
    • 8.3.1 Market Trends
    • 8.3.2 Key Segments
      • 8.3.2.1 Blood Cancer
      • 8.3.2.2 Solid Tumor
      • 8.3.2.3 Others
    • 8.3.3 Market Forecast
  • 8.4 CNS Conditions
    • 8.4.1 Market Trends
    • 8.4.2 Key Segments
      • 8.4.2.1 Epilepsy
      • 8.4.2.2 Parkinson's Disease
      • 8.4.2.3 Huntington's Disease
      • 8.4.2.4 Stroke
      • 8.4.2.5 Traumatic Brain Injury
      • 8.4.2.6 ALS
      • 8.4.2.7 Muscle Regeneration
      • 8.4.2.8 Others
    • 8.4.3 Market Forecast
  • 8.5 Diabetes
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Obesity
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Charles River Laboratories International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Evotec SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 ICON plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Iris Pharma (ABIONYX Pharma)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Labcorp Drug Development (Laboratory Corporation of America Holdings)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 SWOT Analysis
    • 14.3.6 North American Science Associates LLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Parexel International Corporation
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Pronexus Analytical AB
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Syneos Health
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 WuXi AppTec
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials

List of Figures

  • Figure 1: Global: In-vivo CRO Market: Major Drivers and Challenges
  • Figure 2: Global: In-vivo CRO Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: In-vivo CRO Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: In-vivo CRO Market: Breakup by Type (in %), 2023
  • Figure 5: Global: In-vivo CRO Market: Breakup by GLP Type (in %), 2023
  • Figure 6: Global: In-vivo CRO Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: In-vivo CRO Market: Breakup by Region (in %), 2023
  • Figure 8: Global: In-vivo CRO (Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: In-vivo CRO (Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: In-vivo CRO (Non-Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: In-vivo CRO (Non-Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: In-vivo CRO (Non-GLP) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: In-vivo CRO (Non-GLP) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: In-vivo CRO (GLP Toxicology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: In-vivo CRO (GLP Toxicology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: In-vivo CRO (Pain Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: In-vivo CRO (Pain Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: In-vivo CRO (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: In-vivo CRO (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: In-vivo CRO (CNS Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: In-vivo CRO (CNS Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: In-vivo CRO (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: In-vivo CRO (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: In-vivo CRO (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: In-vivo CRO (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: In-vivo CRO (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: In-vivo CRO (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: In-vivo CRO Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: In-vivo CRO Industry: SWOT Analysis
  • Figure 80: Global: In-vivo CRO Industry: Value Chain Analysis
  • Figure 81: Global: In-vivo CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: In-vivo CRO Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: In-vivo CRO Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: In-vivo CRO Market Forecast: Breakup by GLP Type (in Million US$), 2024-2032
  • Table 4: Global: In-vivo CRO Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: In-vivo CRO Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: In-vivo CRO Market: Competitive Structure
  • Table 7: Global: In-vivo CRO Market: Key Players